PCM
PTLA

Price Capital Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Price Capital Management’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-6,086
Closed -$231K – 248
2015
Q1 		$231K Buy
+6,086
New +$209K 0.14% 221

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Price Capital Management's PTLA Position: Q2 2015 in Review

Price Capital Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2015, closing a stake of 6,086 shares — an estimated $231K sold.

Price Capital Management first reported a position in PTLA in Q1 2015 and held it in 1 quarter. The position peaked at $231K in Q1 2015. 160 funds tracked by Wall St. Rank hold PTLA as of Q2 2015.

  • Price Capital Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
  • Price Capital Management sold 6,086 Portola Pharmaceuticals, Inc. shares in Q2 2015, an estimated $231K.
  • Price Capital Management first reported a position in Portola Pharmaceuticals, Inc. in Q1 2015 and held it in 1 quarter.
  • Price Capital Management's Portola Pharmaceuticals, Inc. position peaked at $231K in Q1 2015.
  • 160 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2015.

Based on Price Capital Management's 13F filing for Q2 2015.